Collectively, our data suggests a model whereby mutational activation of the non-canonical NF-κB pathway contributes to rewiring of the myeloma epigenome through p52-driven enhancer co-option which sustains oncogenic transcriptional programmes. The gene discussed is NFKB1; the disease is plasma cell myeloma.